本帖最后由 诗意栖居 于 2015-2-7 22:42 编辑
REPLICor a biopharmaceutical company targeting a cure for Chronic Hepatitis B patients will present updated human clinical trial data documenting a 4 to 6 log reduction in s-antigen and a long-term SVR in 80% of patients. December 1, 2014 – Recently updated clinical trial data from REPLICor’s Phase 2 trials will be presented at the Piper Jaffray Healthcare Conference Dec 3rd in New York City. REPLICor’s Chief Scientific Officer Dr. Andrew Vaillant Ph.D. will participate in the panel discussion on approaches to treat HBV on Wednesday morning.
REPLICor’s nucleic acid polymer (NAP) HBsAg (s-antigen)-release inhibitors therapy blocks s-antigen release and can effectively eliminate s-antigen from the blood (as an example, the serum HBsAg in one patient was reduced from 87,690 to 0.01 IU / ml on treatment, a 6.94 log reduction). REPLICor has currently tested its NAP technology in three different human clinical trials in Asia using different treatment modalities: in monotherapy, in combination with short-term immunotherapy and in combination with a complete course of Pegasys™ with the latter regimen resulting in the maintenance of long-term SVR in 80% of patients for greater than 6 months after all treatment is withdrawn.
“Our data suggests that eliminating surface antigen will be a critical part of a multi-step process that will be necessary to achieve a high SVR. Eliminating surface antigen will require a multi-log reduction which our drug has been shown to accomplish in human clinical trials,” said Dr. Vaillant. “We look forward to further validation of NAP activity from additional clinical trials over the next 12 months.”
http://replicor.com/
https://clinicaltrials.gov/ct2/show/NCT02233075
简译：
2014年12月1日讯：REPLICor’s 公司2期更新的临床数据表明，REPLICor 的核酸聚合物(NAP，先前的Rep9AC，现在叫REP 2139-Ca），一种HBsAg （表面抗原）释放抑制剂，可以有效清除血液中的HBsAg （观察到其中一个患者血液中的HBsAg从87,690 降到 0.01 IU / ml ，降低 6.94 log）。REPLICor’s目前正在亚洲开展3种临床试验，分别对NAP单药、NAP结合短期免疫治疗、NAP全程结合长效干扰素（Pegasys™ ）的效果进行评估。其中，NAP全程结合Pegasys的效果最好，试验后6个月时，80%的患者血清表抗转阴得到维持。
Dr. Vaillant说：我们的数据表明，表抗清除是实现表抗转阴的关键步骤，这一点我们的药物在人体中得到了实现。在未来一年中，我们将继续考察接下来的结果。（该临床试验将持续到2016年） | 
发表于 2015-2-7 22:17
